CAR-T cell therapy is a successful immunotherapy for treating hematological cancer targeting CD19+ malignancies, such as ALL and CLL used in nearly 200 clinical trials worldwide. The gene discussed is CD19; the disease is hematopoietic and lymphoid cell neoplasm.